CHARM Therapeutics Ltd has appointed Erkut Bahceci as chief medical officer to lead clinical development strategy and execution as the company advances a potential new treatment for acute myeloid leukemia. His appointment follows the company’s $80 million Series B financing. Dr Bahceci joins CHARM from BlueSphere Bio, where he was CMO, overseeing clinical development in haematologic malignancies, rare diseases and solid tumours. Prior to BlueSphere, he was head of oncology development at Takeda Oncology and vice president medical science-haematology at Astellas Pharma US.
Copyright 2025 Evernow Publishing Ltd